A Closer Look at States’ Insulin Price Regulations

Earlier this month, Colorado signed into law a measure that caps total out-of-pocket spending on insulin for all diabetic patients. Under the bill, patients will pay no more than $100 for a month’s insulin supply. List prices for insulin have risen rapidly in recent years, and the average out-of-pocket cost of a full-year supply of insulin reached $613 for a privately insured patient and $1,288 for an uninsured patient, according to a Commonwealth Fund study based on Medical Expenditure Panel Survey from 2014 to 2017. To address the cost burden for diabetics, at least 17 states have implemented some type of monthly copayment cap for insulin. In addition, 46 states and the District of Columbia have insurance mandates related to diabetes coverage.

NOTE: Regular insulin users are those with four or more prescriptions in a year.

SOURCES: “Diabetes State Mandates and Insulin Copayment Caps,” National Conference of State Legislatures, July 2021. Visit https://bit.ly/3f7Ml7l. “Not So Sweet: Insulin Affordability over Time,” The Commonwealth Fund, September 2020. Visit https://bit.ly/2Wv3X6S.

© 2025 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

handshake
December 5

Warranties Can Help Mitigate Risk for Payers, Manufacturers Alike

Read More
businessman-analyzing-company-report-working-with-digital-augmented-reality-graphics
December 5

MMIT Payer Portrait: Intermountain’s Select Health

Read More
old-man-touching-eye
December 5

Even at 10% Discount, Eylea Biosimilar Pavblu Offers Lower-Cost Option

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today